HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
RDY
Dr. Reddy's Laboratories Limited
RDY's fundamentals are weak: its operating margin fell 12 points to 8.9% and free cash flow fell 35%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
RDY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Healthy |
RDY's balance sheet is currently healthy, and its revenue and profitability are stable, but its cash flow is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
RDY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $6.94 | -53% |
| Fair | 31x | $11.07 | -25% |
| Current | 41x | $14.73 | — |
| Expensive | 43x | $15.47 | +5% |
Historical ranges are pointers, not guarantees.
RDY's PE is 41x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
RDY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
RDY has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
RDY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.36 | -52% |
| Q2 2026 | $0.42 | -42% |
| Q1 2026 | $0.55 | -24% |
| Q4 2025 | $0.72 | +4.3% |
| Q3 2025 | $0.75 | +10% |
RDY has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over RDY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
RDY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $923.8M | -1.7% |
| Q2 2026 | $866.1M | -5% |
| Q1 2026 | $814.3M | -10% |
| Q4 2025 | $931M | +4.4% |
| Q3 2025 | $939.3M | +9.8% |
| Q2 2025 | $911.6M | +11% |
| Q1 2025 | $907.4M | +20% |
| Q4 2024 | $891.7M | +16% |
RDY's revenue grew through 2024 and has held roughly level since: $924M last quarter, down 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | -6.2 points |
| Q2 2026 | 3.7% | -17 points |
| Q1 2026 | 0.6% | -20 points |
| Q4 2025 | 16% | -6.1 points |
| Q3 2025 | 20% | -2 points |
| Q2 2025 | 20% | -2.9 points |
| Q1 2025 | 21% | -0.4 points |
| Q4 2024 | 22% | -1.5 points |
RDY has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over RDY on cash flow, with more consistent year-over-year improvement.
RDY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $24.6M | -58% |
| Q2 2026 | -$49.4M | -203% |
| Q1 2026 | $114.7M | 0% |
| Q4 2025 | $38.3M | +$61.7M |
| Q3 2025 | $58M | +286% |
| Q2 2025 | $47.8M | +116% |
| Q1 2025 | $114.7M | +14646% |
| Q4 2024 | -$23.5M | -30999% |
RDY still generates free cash flow, though less than at its 2022 peak: $128M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over RDY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
RDY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +662K shares |
| 1 year | 0% | +313K shares |
| 3 years | +0.2% | +1.4M shares |
RDY has 833M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $14.8M |
| Q4 2024 | — |
RDY hasn't bought back shares in the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
RDY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.1x | Healthy |
| Q2 2026 | 1.0x | Very low |
| Q1 2026 | 0.8x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.4x | Very low |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | 0.4x | Very low |
RDY's net debt is about 1.1 years of its operating earnings (EBITDA), up from less than a year a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
RDY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.4 | Neutral |
| Stochastic | 94.8 | Overbought |
RDY's weekly RSI is 66 (neutral) and its Stochastic is 95 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
RDY PE vs Healthcare Sector
| Metric | RDY | Sector median | Relative |
|---|---|---|---|
| PE | 41x | 26x | 57% above |
| PE % | 74 | 29 | 45 pts above |
RDY is trading at 41x earnings, a 57% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
RDY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.4 | 10% above |
| 20 week MA | $12.8 | 15% above |
| 50 week MA | $13.4 | 10% above |
| 100 week MA | $13.8 | 6.8% above |
| 200 week MA | $13.8 | 7% above |
RDY has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
RDY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.12 | $14.1 | +74% |
| 2021 | $14.1 | $12.6 | -11% |
| 2022 | $12.6 | $10.5 | -16% |
| 2023 | $10.5 | $13.9 | +32% |
| 2024 | $13.9 | $15.9 | +14% |
| 2025 | $15.9 | $14.2 | -11% |
| 2026 YTD | $14.2 | $14.7 | +4% |
RDY has the edge over HIMS on returns for 2026, with the stronger performance.